ArticleJSES reviews, reports, and techniques2025
Influence of demographic and pathological factors on the clinical course and outcomes of the arthroscopic frozen shoulder 360° release.
Article in JSES reviews, reports, and techniques, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Frozen shoulder (FS) is an inflammatory condition that affects the shoulder capsule and can cause significant pain and stiffness. The arthroscopic FS 360° release is indicated in patients with global active range of motion (AROM) limitation. The aim of this study is to determine whether various patient demographic and pathological variables influence patient-reported outcome measures (PROMs) following a complete capsule resection. The variables of interest include patient comorbidity status, conservative therapy prior to surgery, and time from symptom onset to surgical treatment. Methods: An observational prospective cohort study was conducted assessing PROMs and AROM in patients undergoing the 360° arthroscopic release between July 2013 and January 2019. AROM and PROMs including the Oxford Shoulder Score; Western Ontario Shoulder Index; Disabilities of the Arm, Shoulder and Hand; Constant-Murley Score, American Shoulder and Elbow Surgeons score, as well as general measures of pain intensity (visual analog scale) and wellbeing (Euro Quality of Life Measure) were collected preoperatively, 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months postoperatively. Patient demographic variables including comorbidity status (diabetes mellitus, thyroid disorders), preoperative therapy (physiotherapy, cortisone injections), and symptomatic timeframe prior to surgical treatment were also collected. Results: Fifty consented patients underwent the arthroscopic FS 360° release. The mean age was 52.1 ± 7.7 years (range 35-72), and mean body mass index was 27.1 ± 4.7 kg/m Conclusion: The arthroscopic 360° shoulder capsule release is a safe procedure with demonstrated improvements across all PROMs and AROM movements. Patient comorbidity status, prior conservative therapy, and symptomatic timeframe did not influence functional and symptomatic postoperative outcomes 24 months after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.